Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Antimicrobial Chemotherapy Année : 2012

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice

(1) , (2) , (3) , (4, 5) , (6) , (7) , (8) , (9) , (10) , (11) , (1) , (12, 13) , (1) , (14) , (1) , (15) ,
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Isabelle Cohen-Codar
  • Fonction : Auteur

Résumé

Objectives This observational study was requested by French health authorities to determine the impact of lopinavir/ritonavir (Kaletra®) on antiretroviral resistance in clinical practice. Virological failures of lopinavir/ritonavir and their effects on the resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated in protease inhibitor-experienced patients.Patients and methods Virological failure was defined as an HIV-1 plasma viral load >50 copies/mL after at least 3 months of lopinavir/ritonavir-containing antiretroviral therapy. For all patients, a resistance genotypic test was available at failure and before lopinavir/ritonavir treatment. Data from 72 patients with inclusion criteria were studied. Results The mean viral load at baseline was 4 log10 copies/mL (1.6–6.5). Mutations in the protease gene significantly selected between baseline and failure were L10V, K20R, L33F, M36I, I47V, I54V, A71V and I85V (P < 0.05). Patients who had more than seven protease inhibitor mutations at baseline showed a significantly increased risk of occurrence of protease inhibitor mutations. The proportion of viruses susceptible to atazanavir, fosamprenavir and darunavir decreased significantly between baseline and failure (P < 0.05). Among patients with a virus susceptible to atazanavir at day 0, 26% (n = 14) exhibited a virus resistant or possibly resistant at the time of failure. This proportion was 32% (n = 16) for fosamprenavir and 16% (n = 7) for darunavir. Conclusions A darunavir-based regimen appears to be a sequential option in the case of lopinavir/ritonavir failure. To compare and determine the best treatment sequencing, similar studies should be performed for darunavir/ritonavir and atazanavir/ritonavir.

Dates et versions

hal-03268578 , version 1 (23-06-2021)

Identifiants

Citer

Cathia Soulié, Constance Delaugerre, Laurence Morand-Joubert, Charlotte Charpentier, Virginie Ferre, et al.. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. Journal of Antimicrobial Chemotherapy, 2012, 67 (10), pp.2487 - 2493. ⟨10.1093/jac/dks226⟩. ⟨hal-03268578⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More